Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2016—Quest Diagnostics will offer clinical laboratory testing using Dako’s PD-L1 IHC 28-8 pharmDx qualitative test, an FDA-approved complementary in vitro diagnostic test for use in the detection of PD-L1 expression in formalin-fixed, paraffin-embedded melanoma tissue.
March 2016—Bio-Rad Laboratories announced that its D-100 System for A1c testing has obtained FDA clearance to monitor the long-term blood glucose control of individuals with diabetes, as an aid in the diagnosis of diabetes, and to help identify those who may be at risk for developing the disease.
February 2016—Foundation Medicine announced a three-way collaboration with Horizon Healthcare Services and Clinical Outcomes Tracking and Analysis to advance precision medicine, improve clinical outcomes, and deliver enhanced value to the health care system in the treatment of patients with metastatic non-small cell lung cancer.
February 2016—Integrated DNA Technologies introduced PrimeTime Gene Expression Master Mix, an optimized enzyme mix for probe-based qPCR. PrimeTime qPCR Assays are available with a choice of dyes and quenchers, and the predesigned assays are backed by a performance guarantee. The Master Mix integrates into new and existing experimental workflows and is also compatible with all commercially available 5’ nuclease gene expression assays.
February 2016—Novogene and Illumina have entered into an agreement to jointly develop advanced clinical applications in the fields of reproductive health and oncology based on next-generation sequencing technology. The companies will work together to develop a user-friendly diagnostic system for clinical prenatal DNA and oncology testing in the Chinese market.
February 2015—PerkinElmer launched its Vectra 3 automated, high-throughput quantitative pathology imaging system. This solution’s new seven-color multiplexing and visualization capabilities are designed to enable pathologists and oncologists conducting research to gain a deeper level of understanding of disease mechanisms related to new cancer immunotherapy approaches.
February 2016—NeoGenomics has expanded its liquid biopsy testing menu to include two new tests, a NeoLab Solid Tumor Monitor and a NeoLab BTK Inhibitor Acquired Resistance test. Each of the tests uses cell-free DNA from peripheral blood plasma without the need for tissue biopsies.
February 2016—The Clinical and Laboratory Standards Institute has published a new document titled “Management of Critical- and Significant-Risk Results (GP47-Ed1).” This guideline provides current best practice recommendations for developing and implementing a policy and procedures for the identification, reporting, and management of critical- and significant-risk laboratory results.
February 2016—The Clinical and Laboratory Standards Institute has published a new document titled “Management of Critical- and Significant-Risk Results (GP47-Ed1).” This guideline provides current best practice recommendations for developing and implementing a policy and procedures for the identification, reporting, and management of critical- and significant-risk laboratory results.
February 2016—Illumina launched its MiniSeq Sequencing System and, during a presentation at the J.P. Morgan Healthcare Conference, Jan. 11–14 in San Francisco, introduced the Infinium XT and previewed Project Firefly, which will lead to the commercialization of a new semiconductor-based sequencing system.
